Cargando…

Anti-inflammatory potential of Empagliflozin

Detalles Bibliográficos
Autor principal:	Pirklbauer, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997819/ https://www.ncbi.nlm.nih.gov/pubmed/33728540 http://dx.doi.org/10.1007/s10787-021-00797-9

Ejemplares similares

Empagliflozin Inhibits IL-1β-Mediated Inflammatory Response in Human Proximal Tubular Cells
por: Pirklbauer, Markus, et al.
Publicado: (2021)

Impact of empagliflozin on diabetic kidney disease
por: Koya, Daisuke
Publicado: (2017)

One Small Step for Empagliflozin, One Giant Leap for Diabetology
por: Kalra, Sanjay
Publicado: (2015)

Empagliflozin Inhibits Basal and IL-1β-Mediated MCP-1/CCL2 and Endothelin-1 Expression in Human Proximal Tubular Cells
por: Pirklbauer, Markus, et al.
Publicado: (2020)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
por: Ampudia-Blasco, Francisco Javier, et al.
Publicado: (2017)

Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
por: Liang, Bo, et al.
Publicado: (2020)

Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
por: Hattori, Sachiko
Publicado: (2018)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
por: Heimke, Marvin, et al.
Publicado: (2022)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes
por: Giannattasio, Silvia, et al.
Publicado: (2022)

Empagliflozin: a potential anticancer drug
por: Wu, Wenwen, et al.
Publicado: (2023)

An anti-inflammatory role for tranexamic acid in cardiac surgery?
por: Robertshaw, Heidi J
Publicado: (2008)

Anti-inflammatory management for tendon injuries - friends or foes?
por: Chan, Kai-Ming, et al.
Publicado: (2009)

Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk
por: Goldkind, Lawrence, et al.
Publicado: (2006)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

The cholinergic anti-inflammatory pathway alleviates acute lung injury
por: Andersson, Ulf
Publicado: (2020)

Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes
por: Reppo, Ingrid, et al.
Publicado: (2023)

Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes
por: Janić, Miodrag, et al.
Publicado: (2022)

Hemodialysis treatment in patients with severe electrolyte disorders: Management of hyperkalemia and hyponatremia
por: Pirklbauer, Markus
Publicado: (2020)

Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?
por: Yeomans, Neville D
Publicado: (2015)

Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner?
por: Tenenbaum, Alexander, et al.
Publicado: (2017)

Liraglutide exhibits anti-inflammatory activity through the activation of the PKA/CREB pathway
por: Wang, Li, et al.
Publicado: (2019)

Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression
por: Arefin, Adittya, et al.
Publicado: (2023)

Empagliflozin in acute myocardial infarction: the EMMY trial( )
por: von Lewinski, Dirk, et al.
Publicado: (2022)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Drug eruption associated with empagliflozin
por: Yau, Kevin, et al.
Publicado: (2022)

Commentary: A nearly forgotten class of anti-inflammatory lipid molecules in central nervous system
por: Ru, Nan, et al.
Publicado: (2023)

Anti-thyroid autoantibodies as biomarkers for alemtuzumab associated thyroid autoimmunity
por: Reindl, Markus
Publicado: (2019)

Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes
por: Sathish, Thirunavukkarasu, et al.
Publicado: (2021)

Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration
por: Bazan, Nicolas G., et al.
Publicado: (2021)

Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson’s disease in rats
por: Ahmed, Sanaa, et al.
Publicado: (2022)

Glyburide Is Anti-inflammatory and Associated with Reduced Mortality in Melioidosis
por: Koh, Gavin C. K. W., et al.
Publicado: (2011)

TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine
por: Felice, Carla, et al.
Publicado: (2019)

Commentary: Newer non-steroidal anti-inflammatory drugs for postoperative management in phacoemulsification. Are topical corticosteroids still obligatory?
por: Karkhur, Samendra, et al.
Publicado: (2022)

Empagliflozin: Not just a glorified diuretic
por: John, Mathew
Publicado: (2016)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Masked Primary Hyperparathyroidism by Empagliflozin Use
por: Awada, Mariam, et al.
Publicado: (2022)

Role of empagliflozin in chronic lithium toxicity
por: Dyson, Vicki
Publicado: (2022)

The Use of Empagliflozin Post Myocardial Infarction
por: Ravendran, Kapilraj, et al.
Publicado: (2023)

Dextran-70 to modulate inflammatory response after cardiopulmonary bypass: potential for a novel approach?
por: Schuerholz, Tobias, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_5e0hh9oe9l3c8v53tm21rnqgal